India Must Resist TRIPS‑Plus IP Pressures to Protect Biotech and Public Health
The push for TRIPS‑Plus IP provisions threatens innovation and access to affordable healthcare worldwide By Nandan Trivedi India’s remarkable rise as a global pharmaceutical powerhouse is no accident—it is the result of strategic legal foresight, including a refusal to bow to overreaching global IP standards. Now, as India negotiates multiple Free Trade Agreements (FTAs) with …
India Must Resist TRIPS‑Plus IP Pressures to Protect Biotech and Public Health Read More »